- Home
- AMBO vs GOVX Comparison
AMBO vs GOVX Comparison
Compare AMBO & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- GOVX
- Stock Information
- Founded
- AMBO 2000
- GOVX 2001
- Country
- AMBO United States
- GOVX United States
- Employees
- AMBO N/A
- GOVX N/A
- Industry
- AMBO Other Consumer Services
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- GOVX Health Care
- Exchange
- AMBO Nasdaq
- GOVX Nasdaq
- Market Cap
- AMBO 8.3M
- GOVX 7.6M
- IPO Year
- AMBO 2010
- GOVX N/A
- Fundamental
- Price
- AMBO $2.90
- GOVX $0.72
- Analyst Decision
- AMBO
- GOVX Strong Buy
- Analyst Count
- AMBO 0
- GOVX 4
- Target Price
- AMBO N/A
- GOVX $10.50
- AVG Volume (30 Days)
- AMBO 14.0K
- GOVX 2.0M
- Earning Date
- AMBO 01-01-0001
- GOVX 07-28-2025
- Dividend Yield
- AMBO N/A
- GOVX N/A
- EPS Growth
- AMBO N/A
- GOVX N/A
- EPS
- AMBO 0.11
- GOVX N/A
- Revenue
- AMBO $9,392,000.00
- GOVX $6,143,044.00
- Revenue This Year
- AMBO N/A
- GOVX N/A
- Revenue Next Year
- AMBO N/A
- GOVX N/A
- P/E Ratio
- AMBO $26.39
- GOVX N/A
- Revenue Growth
- AMBO 2.50
- GOVX 1943.07
- 52 Week Low
- AMBO $1.00
- GOVX $0.43
- 52 Week High
- AMBO $5.55
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- AMBO 55.26
- GOVX 44.46
- Support Level
- AMBO $2.53
- GOVX $0.72
- Resistance Level
- AMBO $3.00
- GOVX $0.83
- Average True Range (ATR)
- AMBO 0.26
- GOVX 0.07
- MACD
- AMBO 0.01
- GOVX 0.01
- Stochastic Oscillator
- AMBO 68.45
- GOVX 19.96
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.